Last reviewed · How we verify
Ivermectin and Doxycycline
Ivermectin and Doxycycline is a Antiparasitic and antibiotic combination Small molecule drug developed by Bangladesh Medical Research Council (BMRC). It is currently in Phase 3 development for Parasitic and bacterial co-infections (investigational combination therapy). Also known as: Imac and Doxibac.
Ivermectin paralyzes parasites by enhancing GABA-gated chloride channel activity, while doxycycline inhibits bacterial protein synthesis; together they target parasitic and bacterial co-infections.
Ivermectin paralyzes parasites by enhancing GABA-gated chloride channel activity, while doxycycline inhibits bacterial protein synthesis; together they target parasitic and bacterial co-infections. Used for Parasitic and bacterial co-infections (investigational combination therapy).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ivermectin and Doxycycline |
|---|---|
| Also known as | Imac and Doxibac |
| Sponsor | Bangladesh Medical Research Council (BMRC) |
| Drug class | Antiparasitic and antibiotic combination |
| Target | GABA-gated chloride channels (ivermectin); bacterial 30S ribosome (doxycycline) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ivermectin is an antiparasitic agent that binds to glutamate-gated and GABA-gated chloride channels in nematodes and arthropods, causing paralysis and death. Doxycycline is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This combination is being investigated for synergistic activity against parasitic and bacterial infections, potentially including intracellular pathogens.
Approved indications
- Parasitic and bacterial co-infections (investigational combination therapy)
Common side effects
- Nausea
- Diarrhea
- Headache
- Photosensitivity (doxycycline)
- Dizziness
Key clinical trials
- Trial of Combination Therapy to Treat COVID-19 Infection (PHASE1)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
- An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization (PHASE4)
- Oracea Soolantra Association in Participants With Severe Rosacea (PHASE4)
- Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection. (PHASE2)
- Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients (PHASE1, PHASE2)
- Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivermectin and Doxycycline CI brief — competitive landscape report
- Ivermectin and Doxycycline updates RSS · CI watch RSS
- Bangladesh Medical Research Council (BMRC) portfolio CI
Frequently asked questions about Ivermectin and Doxycycline
What is Ivermectin and Doxycycline?
How does Ivermectin and Doxycycline work?
What is Ivermectin and Doxycycline used for?
Who makes Ivermectin and Doxycycline?
Is Ivermectin and Doxycycline also known as anything else?
What drug class is Ivermectin and Doxycycline in?
What development phase is Ivermectin and Doxycycline in?
What are the side effects of Ivermectin and Doxycycline?
What does Ivermectin and Doxycycline target?
Related
- Drug class: All Antiparasitic and antibiotic combination drugs
- Target: All drugs targeting GABA-gated chloride channels (ivermectin); bacterial 30S ribosome (doxycycline)
- Manufacturer: Bangladesh Medical Research Council (BMRC) — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Parasitic and bacterial co-infections (investigational combination therapy)
- Also known as: Imac and Doxibac
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing